GALAD Model for Hepatocellular Carcinoma (HCC)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years
حداقل ۰.۱ — حداکثر ۱۰۰۰۰۰ • واحد: ng/mL
حداقل ۰ — حداکثر ۱۰۰ • واحد: percentage
حداقل ۱ — حداکثر ۱۰۰۰۰۰ • واحد: mAU/mL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk-50–-0.63
- High Risk-0.63–50
The GALAD Model for Hepatocellular Carcinoma (HCC) calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include age. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.
Clinical Indication
The GALAD Model for Hepatocellular Carcinoma (HCC) is indicated for bedside clinical practice to support Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: GALAD score ≥-0.63 suggests high probability of HCC with 85.6% sensitivity and 93.3% specificity.
Z = -10.08 + 0.09 × age + 1.67 × sex + 2.34 × log₁₀(AFP) + 0.04 × AFP-L3 + 1.33 × log₁₀(DCP), where sex = 1 for males, 0 for females
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient's age in years(years) |
| sex | string | Yes | Patient's biological sex (males have higher HCC risk) |
| afp | float | Yes | Alpha-fetoprotein level in ng/mL. Standard serum tumor marker for HCC evaluation(ng/mL) |
| afp_l3_percentage | float | Yes | AFP-L3 percentage (%). Most useful when total AFP ≤200 ng/mL. ≥10% associated with 7-fold increased HCC risk(percentage) |
| dcp | float | Yes | Des-gamma-carboxy prothrombin (PIVKA-II) level in mAU/mL. Abnormal prothrombin form used as HCC biomarker(mAU/mL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| -50–-0.63 | Low Risk | Low probability of HCC |
| -0.63–50 | High Risk | High probability of HCC |
Evidence-Based References (EBM)
- Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144-53. doi: 10.1158/1055-9965.EPI-13-0870.DOI: 10.1158/1055-9965.EPI-13-0870
- Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020;18(3):728-735.e4. doi: 10.1016/j.cgh.2019.08.012.DOI: 10.1016/j.cgh.2019.08.012
- Yang JD, Addissie BD, Mara KC, et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019;28(3):531-538. doi: 10.1158/1055-9965.EPI-18-0281.DOI: 10.1158/1055-9965.EPI-18-0281